RTTNews | Jan 19, 2021 10:24AM EST

10:23 Tuesday, January 19, 2021 (RTTNews.com) - Shares of clinical-stage drug discovery company Lixte Biotechnology Holdings, Inc. (LIXT) are rising more than 15% Tuesday morning after the company announced an agreement with cancer research and treatment center, City of Hope to begin Phase 1b study of LB-100 in small cell lung cancer.

The trial will assess the combination of Lixte's first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).

LB-100 will be given in combination with carboplatin, etoposide and atezolizumab, an FDA approved but marginally effective regimen, in previously untreated ED-SCLC.

LIXT, currently at $3.61, has traded in the range of $0.80- $7.86 in the last one year.

Read the original article on RTTNews ( https://www.rttnews.com/3161525/stock-alert-lixte-biotechnology-adds-15-following-deal-with-city-of-hope.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved